Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Refractory and Relapsed Chronic Lymphocytic Leukemia (CLL)

Trial Profile

Pilot Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Refractory and Relapsed Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Obinutuzumab (Primary) ; Interleukin-15
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 26 Feb 2019.
    • 24 Jan 2019 Planned initiation date changed from 23 Jan 2019 to 1 Feb 2019.
    • 17 Jan 2019 Planned initiation date changed from 4 Jan 2019 to 23 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top